Haloperidol for Delirium in Adult Critically Ill Patients
Status:
Active, not recruiting
Trial end date:
2021-02-04
Target enrollment:
Participant gender:
Summary
The EuRIDICE trial will study whether haloperidol as a first line treatment for ICU delirium
reduces delirium duration (and severity). Adverse outcomes typically associated with delirium
will also be studied and include long term cognition, functional outcome and quality of life.
Further, patient and family experiences and cost-effectiveness will be assessed. Finally,
safety concerns associated with the use of haloperidol in this vulnerable population will be
studied.
Phase:
Phase 3
Details
Lead Sponsor:
Erasmus Medical Center
Collaborator:
ZonMw: The Netherlands Organisation for Health Research and Development